Общество с ограниченной ответственностью; "Международный биотехнологический центр "Генериум" ("МБЦ "Генериум") (RU)
发明人:
Вишневский Александр Юрьевич (RU),Карпов Андрей Павлович (RU),Лыков Максим Валерьевич (RU),Морозов Антон Николаевич (RU),Петров Андрей Владимирович (RU),Потеряев Дмитрий Александрович (RU),Ручко Серге
申请号：
RU2015151459
公开号：
RU2015151459A
申请日:
2015.12.01
申请国别(地区):
RU
年份:
2017
代理人:
摘要：
The invention relates to biotechnology and, in particular, can be used in the pharmaceutical industry for preparing a drug for treating a B-cell disorder, depleting B-cells or slowing the development of a pathological condition associated with B-cell abnormalities. A bispecific antibody specifically binding to CD3 and CD19 comprises two chains connected by disulphide bonds. Each chain contains light and heavy chain variable domains of antibodies against CD3 and CD19, linker sequences, an immunoglobulin IgG hinge region and an immunoglobulin IgG Fc domain constant region. The antibody is produced with the aid of recombinant DNA technology using a nucleic acid that codes for the antibody and/or using a vector containing said nucleic acid, which are introduced into a host cell. A method of producing the antibody includes at least cultivating a host cell and isolating the target product. A method of purifying the antibody includes at least a chromatography stage. The antibody is used to treat a B-cell disorder, deplete B-cells or slow the development of a pathological condition associated with B-cell abnormalities. A corresponding pharmaceutical composition contains said antibody and a pharmaceutically acceptable carrier. A method of treating disorders includes administering to a patient in need thereof a therapeutically effective amount of the antibody. The invention provides for more convenient anti-CD3*CD19 therapy as a result of an anti-CD3*CD19 antibody with an increased half-life and an enhanced cytotoxic effect, which has high bioavailability even when administered subcutaneously.
